Drug Trial News

RSS

Lund University professor to coordinate oral insulin study for type 1 diabetes

Type 1 diabetes is the autoimmune form of diabetes, in which the patients' insulin-producing beta cells are destroyed by their own immune system. "We know that if a person has two autoantibodies and one of them is against insulin, there is a 50 per cent risk that they will develop type 1 diabetes within five years. It doesn't matter how old you are", says Ake Lernmark, Professor of Experimental Diabetes Research at Lund University in Sweden.

20 Sep 2012

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME).

20 Sep 2012

APR-246 can restore function of defective p53 and activate apoptosis in cancer cells

The p53 gene plays a key role in the prevention of cancer, by blocking cell growth and triggering programmed cell death or apoptosis. If, however, p53 has mutated and become defective, the cancer cells can acquire the ability to evade apoptosis and become more resistant to therapy.

20 Sep 2012

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the Food and Drug Administration's Division of Neurology Products concerning the development strategy for lasmiditan at a recently completed End of Phase 2 meeting.

19 Sep 2012

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

19 Sep 2012

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that enrollment has commenced at two sites participating in its Phase 2, open-label, safety and efficacy PET imaging study of [18F]NAV4694 for detection of cerebral β-amyloid plaque in subjects diagnosed with probable Alzheimer's disease (AD).

19 Sep 2012

Abiraterone acetate confirmed to offer significant survival benefit to advanced prostate cancer patients

Results of a phase 3 trial published in The Lancet Oncology have confirmed that the drug abiraterone acetate (marketed as Zytiga®) offers a significant survival benefit to patients with castration-resistant prostate cancer, which is spreading to other parts of their body (known as metastatic prostate cancer).

18 Sep 2012

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.

18 Sep 2012

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

In the first clinical trial to demonstrate an effective treatment for constant, disabling cough among people with idiopathic pulmonary fibrosis (IPF), researchers at the Johns Hopkins University School of Medicine found that taking thalidomide significantly reduced the cough and improved quality of life.

18 Sep 2012

Apixaban offers minor added benefit for adult patients after hip replacement

The clot-inhibiting drug apixaban was approved in May 2011 for the prevention of thrombosis (blood clots) after operations to replace a hip or knee joint.

18 Sep 2012

Positive data from Aprea’s APR-246 Phase I/II study on blood or prostate cancer

Aprea today announced positive data from a completed Phase I/II clinical study with its investigational drug APR-246. The results from the study have been published in the Journal of Clinical Oncology.

18 Sep 2012

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Pfizer Oncology today announced that important data from its lung cancer and renal cell carcinoma (RCC) portfolios will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress in Vienna, Austria, September 28 - October 2, 2012.

18 Sep 2012

Compelling data from two ITS Flunisyn Phase I clinical trials against multiple strains of influenza A

Immune Targeting Systems Limited, an emerging leader in the development of vaccines that promote T-cell responses against viruses and cancers, today announces compelling data from two Phase I clinical trials of FlunisynTM, the Company's lead vaccine programme which elicits potent immune responses against multiple strains of influenza-A virus.

18 Sep 2012

Anthera to initiate blisibimod Phase 3 program for systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.

17 Sep 2012

vasopharm's explorative phase IIa NOSTRA trial in TBI meets clinical endpoints for safety

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.

17 Sep 2012

Positive results from Targacept TC-5619 Phase 2 trial for inattentive-predominant attention deficit/hyperactivity disorder

Targacept, Inc. today announced top-line results from a Phase 2 trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity disorder (ADHDi). In the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the inattention subscale of the Conners' Adult ADHD Rating Scale-Investigator-Rated (CAARS-INV), after four weeks of treatment versus placebo.

17 Sep 2012

Jennerex Phase 2 JX-594 clinical data for hepatocellular carcinoma presented at ILCA meeting

Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic immunotherapies, presented Phase 2 clinical data of JX-594 delivered first intravenously and subsequently through intra-tumoral route demonstrating safety as well as disease control and tumor responses in patients with hepatocellular carcinoma (liver cancer, HCC).

17 Sep 2012

Study estimates drug concentrations of Truvada and tenofovir to reduce risk of HIV among MSM

Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP.

15 Sep 2012

UMDNJ, Proteonomix to conduct UMK-121 Phase 1 trial in end-stage liver disease

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced it has entered into an agreement with Piscataway, N.J.-based University of Medicine and Dentistry of New Jersey (UMDNJ) to conducted a Phase 1 clinical trial with its proprietary, patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD).

15 Sep 2012

Clinical trial results signal 'promise, unresolved challenges' in finding effective dengue vaccine

The first-ever results from a dengue virus vaccine clinical trial aimed at showing effectiveness "provide signals rather than definitive answers, and a mixture of both promise and unresolved challenges," Orin Levine, executive director of the International Vaccine Access Center, and Ciro de Quadros, executive vice president of the Sabin Vaccine Institute, write in the Huffington Post "Impact" blog.

14 Sep 2012

Drug Trial News

Lund University professor to coordinate oral insulin study for type 1 diabetes

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

APR-246 can restore function of defective p53 and activate apoptosis in cancer cells

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Navidea commences enrollment in [18F]NAV4694 Phase 2 study for Alzheimer's

Abiraterone acetate confirmed to offer significant survival benefit to advanced prostate cancer patients

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

Apixaban offers minor added benefit for adult patients after hip replacement

Positive data from Aprea’s APR-246 Phase I/II study on blood or prostate cancer

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Compelling data from two ITS Flunisyn Phase I clinical trials against multiple strains of influenza A

Anthera to initiate blisibimod Phase 3 program for systemic lupus erythematosus

vasopharm's explorative phase IIa NOSTRA trial in TBI meets clinical endpoints for safety

Positive results from Targacept TC-5619 Phase 2 trial for inattentive-predominant attention deficit/hyperactivity disorder

Jennerex Phase 2 JX-594 clinical data for hepatocellular carcinoma presented at ILCA meeting

Study estimates drug concentrations of Truvada and tenofovir to reduce risk of HIV among MSM

UMDNJ, Proteonomix to conduct UMK-121 Phase 1 trial in end-stage liver disease

Clinical trial results signal 'promise, unresolved challenges' in finding effective dengue vaccine

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News